Viral Attenuation
Viral Attenuation is a methodological strategy in oncolytic virotherapy involving the reduction of viral pathogenicity while preserving replicative capacity and immunogenicity, typically through genetic modifications or serial passaging to enable selective tumor cell targeting.
199
Publications
11.3K
Citations
1.2K
Authors
345
Institutions
Publications per year
2017–2026
43
Parents
199
Jeanne M. Lusher, Steven Arkin, Charles F. Abildgaard et al. · New England Journal of Medicine · 1993 · 494 citations · Full text
The Genomes of Sheeppox and Goatpox Viruses
E. R. Tulman, Claudio L. Afonso, Zhiqiang Lu et al. · Journal of Virology · 2002 · 389 citations · Full text
1–5 of 199
1.2K
National Institute for Biological Standards and Control, United Kingdom
10 publications · 795 citations
10
h-index
7
h-index
National Institute for Biological Standards and Control, United Kingdom
5 publications · 648 citations
5
h-index
National Institute for Biological Standards and Control, United Kingdom
5 publications · 263 citations
5
h-index
5
h-index
1–5 of 1.2K
345
National Institute for Biological Standards and Control
Potters Bar, United Kingdom
12 h-index
53 publications
3.8K citations
Mayo Clinic
Rochester, United States
8 h-index
27 publications
3K citations
Institut Pasteur
Paris, France
6 h-index
29 publications
1.6K citations
University of Reading
Reading, United Kingdom
6 h-index
23 publications
2.1K citations
Inserm
Paris, France
6 h-index
26 publications
1.1K citations
Columbia University
New York, United States
5 h-index
13 publications
2.8K citations
Mayo Clinic in Arizona
Scottsdale, United States
5 h-index
15 publications
885 citations
Center for Biologics Evaluation and Research
Silver Spring, United States
5 h-index
20 publications
590 citations
1–8 of 345
JVI · 41 publications · 3.2K citations
30
h-index
11 publications · 639 citations
10
h-index
Repository · 10 publications · 202 citations
10
h-index
8 publications · 512 citations
9
h-index
PNAS · 7 publications · 750 citations
7
h-index
1–5